DKK1 and systemic sclerosis: Our data indicate that the upregulation of Dkk-1 may represent a specific effect of RTX treatment, as it was not observed in patients with SSc who were receiving standard treatment including cyclophosphamide; however, our results should be interpreted with caution, taking into account the limited number of patients assessed.